Add Formweb to your mobile device
HIGH ALERT: Please review policy carefully.
Search results for:
fentaNYL
fentaNYL
| Drug Name | Form | Strength |
|---|---|---|
| FentaNYL | FILM, EXTENDED RELEASE, TRANSDERMAL | 12 mcg/hr |
| FentaNYL | FILM, EXTENDED RELEASE, TRANSDERMAL | 25 mcg/hr |
| FentaNYL | FILM, EXTENDED RELEASE, TRANSDERMAL | 50 mcg/hr |
| FentaNYL | FILM, EXTENDED RELEASE, TRANSDERMAL | 75 mcg/hr |
| FentaNYL | FILM, EXTENDED RELEASE, TRANSDERMAL | 100 mcg/hr |
| FentaNYL | INJECTION, INTRAVENOUS | 10 mcg/mL in 0.9% Sodium Chloride 100 mL |
| FentaNYL Citrate (Dilution) | SOLUTION, INJECTABLE | 5 mcg/mL |
| FentaNYL Citrate (Dilution) | SOLUTION, INJECTABLE | 10 mcg/mL |
| FentaNYL Citrate | SOLUTION, INJECTABLE | 50 mcg/mL |
High Alert Drug
: Policy
Last updated: Sep. 5, 2023
- Black Box Warning: Buccal Tablet: Serious adverse events, deaths; abuse potential
- Black Box Warning: Nasal Spray: Schedule II Controlled Substance: Abuse potential
- Black Box Warning: Sublingual Spray: Risk of respiratory depression, medication errors, abuse potential
- Black Box Warning: Transdermal: High concentration of Schedule II opioid agonist
- Patient Education: Medication Card
